MCM2 and breast cancer: And the dysfunction of MCM2 was found to be correlated with the progression and poor prognoses of many cancer types, such as lung cancer (Ramnath et al. 2001; Huang et al. 2021), HCC (Tang et al. 2022; Quaglia et al. 2006), cervical cancer (He et al. 2020; Shroyer et al. 2006), breast cancer (Issac et al. 2019; Gonzalez et al. 2003), oral squamous cell carcinoma (Kodani et al. 2003; Scott et al. 2006), prostate cancer (Toubaji et al. 2012; Long et al. 2020) and pancreatic cancer (Deng et al. 2020; Peng et al. 2016).